Recombinant Human IL18 Protein，His

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in the immune response, particularly in promoting the production of interferon-gamma (IFN-γ) from T and natural killer (NK) cells. Initially discovered for its ability to induce IFN-γ production, IL-18 is produced as a precursor and requires cleavage by caspase-1 for its activation. The cytokine is involved in various physiological processes, including the regulation of Th1 responses, enhancement of innate immunity, and modulation of inflammatory diseases. Due to its significant role in immune regulation, IL-18 has been studied in the context of several conditions, including infectious diseases, autoimmune disorders, and cancer. The research on recombinant IL-18 protein has gained traction as scientists seek to examine its therapeutic potential and underlying mechanisms of action. Recombinant forms of IL-18 are essential for in vitro studies, allowing researchers to explore its effects on immune cell behavior, cytokine production, and potential synergies with other immunotherapeutics. Furthermore, the development of IL-18 as a candidate for cancer immunotherapy is particularly promising, given its ability to enhance anti-tumor immune responses. However, the dual role of IL-18 in promoting both protective and pathological immune responses underscores the complexity of its application in clinical settings. Ongoing studies aim to elucidate the precise mechanisms by which IL-18 influences various immune pathways, as well as optimizing its therapeutic applications while minimizing potential adverse effects. Overall, the continued exploration of recombinant IL-18 protein is vital for advancing our understanding of immune regulation and developing novel therapeutic strategies for immune-related diseases.